Skip to main content

Integra LifeSciences to Spotlight Neurosurgical Product Portfolio at the Congress of Neurological Surgeons (CNS) Annual Meeting

Written by Customer Service on . Posted in Public Companies.

Featuring Durepair® Dura Regeneration Matrix and Mayfield® Ghost™ Base Unit, Post

PRINCETON, N.J., Oct. 08, 2025 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, is pleased to announce its exhibition at the CNS Annual Meeting, from October 11 through 15, 2025, in Los Angeles, California. The company’s booth will spotlight its industry-leading products, while featuring two recent additions to the portfolio – Durepair Dura Regeneration Matrix and Mayfield Ghost Base Unit, Post.

Durepair Dura Regeneration Matrix is a strong suturable graft1 that complements Integra’s extensive portfolio of dural grafts and sealants, and the Mayfield Ghost device is engineered with minimal artifact materials to support clear visualization of anatomical structure for surgical procedures.

“CNS is an excellent opportunity for our team to connect with the neurosurgical community—experts who are just as passionate as we are about restoring patient lives,” said Mike McBreen, executive vice president and president, Codman Specialty Surgical. “The conference is also a great platform to showcase our latest innovations and demonstrate our dedication to advancing neurosurgical care through medical technologies.”

At CNS, Integra will be located at booth #713. Attendees can learn more about several of the company’s medical technologies, including the CereLink® ICP Monitoring System, CUSA® Clarity Tissue Ablation System, Aurora® Surgiscope System, and the Certas® Plus Programmable Valve.

About Integra LifeSciences
At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and regenerative care. We offer a comprehensive portfolio of high quality, leadership medical technology brands. For the latest news and information about Integra and its products, please visit www.integralife.com.

1 Zerris et al. J of Biomed Mat Rsch 2007; 83B (2):580-588 (Canine Study)

Investor Relations:
Chris Ward
(609) 772-7736
chris.ward@integralife.com

Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.